Dispersion Following ESP Versus ITP Blocks Using Lidocaine Study
Launched by DUKE UNIVERSITY · Feb 20, 2025
Trial Information
Current as of July 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating two different techniques for providing pain relief after surgery using regional anesthesia, specifically focusing on how well each technique targets specific areas of the body. The two methods being compared are called the Erector Spinae Plane (ESP) block and the Intertransverse Process (ITP) block. Both techniques aim to numb the chest wall but do so in slightly different ways. The researchers want to see how well each method works in healthy adults by testing the areas of skin that become numb after receiving these blocks.
To be eligible for the study, participants must be at least 18 years old and able to give written consent. They should be in generally good health, without certain medical conditions that could complicate the procedure. Participants will receive both types of blocks on different days, with at least a week in between, and they will undergo tests to assess how well each block works. The study aims to ensure that both techniques are safe and to gather information about how the medication used (lidocaine) is absorbed in the body.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability to provide written informed consent
- • Ability and willingness to comply with the study procedures and duration requirements
- • ASA physical status 1 or 2
- • Age ≥ 18 years
- Exclusion Criteria:
- • BMI \> 35kg.m2
- • Use of analgesics within 24 hours before the procedure
- • History of thoracic trauma or surgery
- • Thoracic deformities or abnormalities that may prevent proper block performance
- • Thoracic tattoos
- • Systemic neuromuscular disease
- • Contraindications to regional anesthesia (e.g., infection, allergy, challenging sonoanatomy)
- • Other known health conditions that would affect the participant's ability to successfully complete the study
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Trial Officials
Brian Mendelson, MD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported